Spots Global Cancer Trial Database for advanced colorectal cancer
Every month we try and update this database with for advanced colorectal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Identification of New Patient Stratification Tools in MSS RAS mt mCRC | NCT03699111 | Advanced Colore... | 18 Years - | Cancer Trials Ireland | ||
| Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer | NCT02619435 | Advanced Colore... | regorafenib | 18 Years - 70 Years | National Cancer Institute, Naples | |
| A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors | NCT00309179 | Advanced Colore... | E7820 plus cetu... | 18 Years - | Eisai Inc. | |
| Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells | NCT01286883 | Colorectal Canc... | 18 Years - | Milton S. Hershey Medical Center | ||
| Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study | NCT04764006 | Advanced Colore... | Surufatinib | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical | NCT02748772 | Colorectal Neop... | Two Anti-angiog... Pure chemothera... | 18 Years - 75 Years | The First People's Hospital of Hefei | |
| Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer | NCT00824161 | Advanced Colore... | TAS-109 | 18 Years - | Taiho Pharmaceutical Co., Ltd. | |
| Study of Nimotuzumab to Treat Colorectal Cancer | NCT00972465 | Advanced Colore... | Nimotuzumab and... | 18 Years - | Peking University | |
| Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical | NCT02748772 | Colorectal Neop... | Two Anti-angiog... Pure chemothera... | 18 Years - 75 Years | The First People's Hospital of Hefei | |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | NCT00707889 | Advanced Colore... Adenocarcinoma ... Adenocarcinoma ... | ABT-869 bevacizumab oxaliplatin folinic acid fluorouracil ABT-869 | 18 Years - | AbbVie | |
| ANGIOPREDICT. ICORG 12-16, V3 | NCT01822444 | Advanced Colore... | Biomarker analy... | 18 Years - | Cancer Trials Ireland | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer | NCT05928312 | Advanced Colore... | Fruquintinib Co... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer | NCT00536809 | Neoplasms, Colo... | lapatinib oxaliplatin capecitabine | 18 Years - | GlaxoSmithKline | |
| wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients | NCT01736904 | Colorectal Canc... | wXELIRI regimen FOLFIRI regimen | 18 Years - 70 Years | Fudan University | |
| A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer | NCT04324476 | Advanced Colore... | Bevacizumab、Oxa... | 18 Years - 75 Years | Jiangsu Cancer Institute & Hospital | |
| Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors | NCT01859858 | Advanced Colore... | curcumin Irinotecan | 21 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Screening Platform for Clinical Trials in Advanced Colorectal Cancer | NCT01723969 | Colorectal Canc... Advanced Colore... | Tumour markers ... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer | NCT01531777 | Colorectal Canc... | Apatinib apatinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | NCT02038699 | Advanced Gliobl... Advanced Colore... Advanced Triple... Advanced Non-sm... | ONC201 | 18 Years - | Chimerix | |
| High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 | NCT03329183 | Colorectal Canc... | Irinotecan | 18 Years - | Shanghai Changzheng Hospital | |
| Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer | NCT00208546 | Colorectal Canc... | 21Capecitabine ... 1Capecitabine +... | 18 Years - | Dutch Colorectal Cancer Group | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial | NCT00386828 | Advanced Colore... | Bevacizumab: | 18 Years - | British Columbia Cancer Agency | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study of PPX in Women With Metastatic Colorectal Cancer | NCT00598247 | Advanced Colore... | Paclitaxel Poli... | 18 Years - | University of Southern California | |
| Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | NCT05350917 | HER2-positive o... | Tislelizumab | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status | NCT04252456 | Advanced Colore... | Aflibercept, 5f... | 18 Years - | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | |
| Second-line Surufatinib Combined With Chemotherapy in Advanced CRC | NCT04734249 | Advanced Colore... | Surufatinib(HMP... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| ANGIOPREDICT. ICORG 12-16, V3 | NCT01822444 | Advanced Colore... | Biomarker analy... | 18 Years - | Cancer Trials Ireland | |
| High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study | NCT00286000 | Advanced Colore... | Administration ... | 18 Years - 69 Years | University Hospital, Ghent | |
| Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency | NCT00952016 | Advanced Colore... | Methotrexate | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules | NCT05495672 | Advanced Colore... Circulating Tum... | Local treatment | 18 Years - 80 Years | Fudan University | |
| Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | NCT03126071 | Advanced Colore... | Raltitrexed Irinotecan Oxaliplatin Bevacizumab | 18 Years - 70 Years | Jiangsu Cancer Institute & Hospital | |
| Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan | NCT06199973 | Advanced Colore... | SHR-A1811 TAS-102, Regora... | 18 Years - 75 Years | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | |
| Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors | NCT01859858 | Advanced Colore... | curcumin Irinotecan | 21 Years - 99 Years | UNC Lineberger Comprehensive Cancer Center | |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | NCT06207656 | Colorectal Canc... | EBC | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies | NCT05028933 | Advanced Hepato... Advanced Colore... Advanced Gastri... Advanced Pancre... | EPCAM CAR-T | 18 Years - 70 Years | Zhejiang University | |
| A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer | NCT02138422 | Symptomatic Col... Advanced Colore... Colorectal Canc... | Xilonix Placebo | 18 Years - | Janssen Research & Development, LLC | |
| A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer | NCT02138422 | Symptomatic Col... Advanced Colore... Colorectal Canc... | Xilonix Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | NCT02654639 | Metastatic Colo... | TAS-102 Bevacizumab | 18 Years - | Georgetown University | |
| Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer | NCT02619435 | Advanced Colore... | regorafenib | 18 Years - 70 Years | National Cancer Institute, Naples | |
| Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | NCT02654639 | Metastatic Colo... | TAS-102 Bevacizumab | 18 Years - | Georgetown University | |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | NCT00707889 | Advanced Colore... Adenocarcinoma ... Adenocarcinoma ... | ABT-869 bevacizumab oxaliplatin folinic acid fluorouracil ABT-869 | 18 Years - | AbbVie | |
| Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer | NCT05364489 | Advanced Colore... | Bevacizumab com... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | NCT05194995 | Advanced Colore... Small Intestina... Appendiceal Can... | JAB-21822 Cetuximab | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan. | NCT05731336 | Advanced Colore... | 18 Years - | Sun Yat-sen University | ||
| IMC001 for Clinical Research on Advanced Digestive System Malignancies | NCT05028933 | Advanced Hepato... Advanced Colore... Advanced Gastri... Advanced Pancre... | EPCAM CAR-T | 18 Years - 70 Years | Zhejiang University | |
| A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer | NCT04337879 | Advanced Colore... | AL2846 Calcium folate 5-FU Oxaliplatin Irinotecan | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells | NCT01286883 | Colorectal Canc... | 18 Years - | Milton S. Hershey Medical Center | ||
| ANGIOPREDICT. ICORG 12-16, V3 | NCT01822444 | Advanced Colore... | Biomarker analy... | 18 Years - | Cancer Trials Ireland | |
| Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | NCT02654639 | Metastatic Colo... | TAS-102 Bevacizumab | 18 Years - | Georgetown University | |
| A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | NCT03035279 | Colorectal Canc... | SC-006 ABBV-181 | 18 Years - | AbbVie | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| Methotrexate in Metastatic Colorectal Cancer With MSH2 Deficiency | NCT00952016 | Advanced Colore... | Methotrexate | 18 Years - | Royal Marsden NHS Foundation Trust | |
| JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | NCT05194995 | Advanced Colore... Small Intestina... Appendiceal Can... | JAB-21822 Cetuximab | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients | NCT01736904 | Colorectal Canc... | wXELIRI regimen FOLFIRI regimen | 18 Years - 70 Years | Fudan University | |
| A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer | NCT00498407 | Advanced Colore... Colorectal Canc... | CP-4055 | 18 Years - | Clavis Pharma | |
| Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | NCT03126071 | Advanced Colore... | Raltitrexed Irinotecan Oxaliplatin Bevacizumab | 18 Years - 70 Years | Jiangsu Cancer Institute & Hospital | |
| Rehabilitation for People With Advanced Cancer | NCT05424068 | Advanced Breast... Advanced Colore... Cancer Rehabili... | In-person rehab... Virtual rehabil... | 18 Years - | University Health Network, Toronto | |
| Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical | NCT02748772 | Colorectal Neop... | Two Anti-angiog... Pure chemothera... | 18 Years - 75 Years | The First People's Hospital of Hefei | |
| Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | NCT06369259 | Advanced Colore... | Defactinib Cetuximab Avutometinib | 18 Years - | M.D. Anderson Cancer Center | |
| Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical | NCT02748772 | Colorectal Neop... | Two Anti-angiog... Pure chemothera... | 18 Years - 75 Years | The First People's Hospital of Hefei | |
| Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma | NCT00312000 | Advanced Colore... | capecitabine-ir... capecitabine+ir... | 18 Years - | Dutch Colorectal Cancer Group | |
| Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer | NCT02923622 | Advanced Colore... Traditional Chi... | Traditional Chi... Integrated trad... Western medicin... | 18 Years - 80 Years | Xiyuan Hospital of China Academy of Chinese Medical Sciences | |
| Efficacy Study of TKcell in Advanced Colorectal Cancer | NCT00854971 | Advanced Colore... | TKCell | 19 Years - 80 Years | Binex | |
| S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer | NCT01193452 | Colorectal Canc... | S-1, Leucovorin leucovorin, 5-f... | 65 Years - | Fudan University | |
| Second-line Surufatinib Combined With Chemotherapy in Advanced CRC | NCT04734249 | Advanced Colore... | Surufatinib(HMP... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Screening Platform for Clinical Trials in Advanced Colorectal Cancer | NCT01723969 | Colorectal Canc... Advanced Colore... | Tumour markers ... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules | NCT05495672 | Advanced Colore... Circulating Tum... | Local treatment | 18 Years - 80 Years | Fudan University | |
| Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | NCT02227667 | Advanced Colore... | MEDI4736 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating EKB-569 in Advanced Colorectal Cancer | NCT00072748 | Colorectal Neop... Colonic Neoplas... Rectal Neoplasm... | EKB-569 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer | NCT05364489 | Advanced Colore... | Bevacizumab com... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients | NCT01736904 | Colorectal Canc... | wXELIRI regimen FOLFIRI regimen | 18 Years - 70 Years | Fudan University | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer | NCT03524274 | Advanced Colore... | Activated CIK a... Cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
